Skip to main content
    C

    Celularity Inc (CELUW)

    Official site

    BIOTECHNOLOGY • NASDAQ

    $0.00
    +0.00 (+0.00%)

    Last updated: Jul 23, 2026 at 5:00 PM ET

    Celularity Inc (CELUW) Financials: Revenue, Profit and Cash Flow

    Updated Mar 31, 2026. Financial statements from company filings, amounts in US dollars.

    Celularity reported revenue of $26.55M for the fiscal year ended Dec 31, 2025, down 51.0% from the year before. That year, net income was -$91.80M with a net margin of -345.8%, operating cash flow was -$13.25M and free cash flow was -$13.25M. The quarter ended Mar 31, 2026 had revenue of $4.10M and net income of -$24.36M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue grew from $17.55M, a compound annual rate of 6.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$26.55M-51.0%76.0%-230.9%-345.8%
    Dec 2024$54.22M+138.1%72.4%-70.7%-106.8%
    Dec 2023$22.77M+26.7%29.7%-335.9%-862.0%
    Dec 2022$17.98M-15.7%-9.4%-142.4%79.0%
    Dec 2021$21.34M+49.4%54.8%-511.2%-469.3%
    Dec 2020$14.28M-32.5%65.5%-1064.0%-1458.4%
    Dec 2019$21.15M+20.5%70.1%-1249.0%-1001.9%
    Dec 2018$17.55MN/A62.7%0.0%0.0%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$26.55M$54.22M$22.77M$17.98M$21.34M$14.28M$21.15M$17.55M
    Cost of revenue$6.36M$14.99M$16.02M$19.66M$9.65M$4.93M$6.32M$6.55M
    Gross profit$20.19M$39.23M$6.75M-$1.69M$11.68M$9.35M$14.82M$11.00M
    Research and development$15.03M$17.39M$30.46M$78.36M$88.35M$52.71M$46.05M$29.06M
    Operating income-$61.31M-$38.36M-$76.48M-$25.60M-$109.06M-$151.93M-$264.13M-$1.10K
    Net income-$91.80M-$57.89M-$196.29M$14.19M-$100.12M-$208.23M-$211.88M-$1.10K
    EBITDAN/AN/AN/AN/A-$88.11MN/A-$70.98M-$1.10K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$4.10M$4.10M$5.28M$5.74M$18.13M$18.13M$9.30M$12.11M$14.68M$3.79M$3.79M$2.94M
    Gross profit$8.56M-$3.27M$3.27M$494.00K$10.79M$10.79M$5.41M$2.50M$13.04M$184.00K$184.00K$2.14M
    Operating income-$22.06M-$22.06M-$12.90M-$15.86M-$9.28M-$9.47M-$11.53M$13.31M-$7.38M-$99.26M-$16.30M-$42.48M
    Net income-$24.36M-$24.36M-$23.07M-$24.52M-$13.29M-$13.29M-$16.10M$9.55M-$22.01M-$93.88M-$93.88M-$47.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $14.00M exceeded cash and equivalents by $7.83M. Shareholder equity was negative, at -$38.06M, as total liabilities of $145.39M exceeded total assets of $107.33M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$107.33M$132.68M$143.89M$401.07M$414.13M$431.01M$521.50M$24.71K
    Current assets$12.32M$20.56M$19.79M$33.50M$37.24M$72.16M$36.81M$24.71K
    Cash and equivalents$6.17M$738.00K$227.00K$13.97M$37.24M$54.31M$28.13M$24.71K
    Total liabilities$145.39M$123.84M$102.93M$202.16M$314.71M$412.30M$383.63M$150.56K
    Short-term debt$14.00M$6.36MN/A$37.60M$3.05M$3.01MN/AN/A
    Long-term debtN/A$35.93MN/AN/AN/AN/AN/AN/A
    Shareholder equity-$38.06M$8.84M$40.96M$198.90M$99.42M$18.71M$137.86M-$125.85K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$107.33M$107.33M$114.24M$120.28M$132.68M$132.68M$128.84M$143.89M$143.82M$157.19M$157.19M$246.42M
    Total liabilities$145.39M$145.39M$134.33M$145.78M$123.84M$123.84M$111.56M$102.93M$112.57M$126.94M$126.94M$127.92M
    Cash and equivalents$6.17M$6.17M$120.00K$863.00K$738.00K$738.00K$133.00K$227.00K$1.90M$273.00K$273.00K$3.08M
    Shareholder equity-$38.06M-$38.06M-$20.09M-$25.50M$8.84M$8.84M$17.28M$40.96M$31.25M$30.25M$30.25M$118.50M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$13.25M-$6.40M-$38.69M-$137.88M-$110.10M-$63.19M-$1.10M-$543
    Capital expenditures$0$161.00K$4.05M$5.24M$6.20M$27.83M$3$1.92M
    Free cash flow-$13.25M-$6.56M-$42.73M-$143.11M-$116.30M-$91.03M-$1.10M-$1.92M
    Dividends paid$5.90M$0N/A$39.07MN/AN/AN/AN/A
    Investing cash flowN/A$514.00KN/A-$5.24MN/A-$12.81M-$286.85M-$31.18M
    Financing cash flow$18.65M$6.70M$24.09M$119.84M$98.56M$102.01M$288.84M$25.25K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$5.10M-$5.10M-$4.16M-$999.00K$1.59M$1.59M-$144.00K-$4.34M-$4.40M-$8.32M-$8.32M-$11.03M
    Capital expenditures$0$0$56.00K$1$56.00K$56.00K$35.00K$580.00K$39.00K$228.00K$228.00K$31.00K
    Free cash flow-$5.10M-$5.10M-$4.21M-$999.00K$1.54M$1.54M-$179.00K-$4.92M-$4.44M-$8.55M-$8.55M-$11.06M
    Last 12 quarters

    Frequently Asked Questions About CELUW

    What is Celularity's annual revenue?

    Celularity reported revenue of $26.55M for the fiscal year ended Dec 31, 2025.

    How fast is Celularity's revenue growing?

    Revenue was down 51.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 13.9%.

    Is Celularity profitable?

    No. Celularity reported net income of -$91.80M for the fiscal year ended Dec 31, 2025, with a net margin of -345.8%.

    How much free cash flow does CELUW generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.25M minus capital expenditures of $0 produced free cash flow of -$13.25M.

    How much debt does Celularity have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $14.00M and cash and equivalents of $6.17M.